Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other indications. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.
Kaketsuken is a Juridical Foundation which researches, develops, manufactures and supplies biological products such as vaccines for humans and animals, and blood plasma derivatives, based in Kumamoto, Japan. The foundation has pursued the preventive medicine fields of microbiology, immunology and serology, towards the improvement of health and hygiene, and presently is a leading company in these fields of human vaccines, animal vaccines, and blood plasma derivatives respectively in the Japanese market. Kaketsuken is also developing therapeutic antibodies. For further information about Kaketsuken, please visit the company's web site at: http://www.kaketsuken.or.jp/eng.
This release includes forward-looking statements concerning the
development of a recombinant form of ADAMTS13. The statements are based on
assumptions about many important factors, including the following, which
could cause actual results to differ materially from those in the
forward-looking statements: satisfaction of regulatory and other
requirements for timely commencement of clinical trials; additional
results, including results in humans, demonstrating the safety and efficacy
of the product;
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved